Tracer library / [177Lu]Lu-3p-C-NETA-ePSMA-16

[177Lu]Lu-3p-C-NETA-ePSMA-16

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Prostate cancer Preclinical only, no clinical indication yet

What it is

Compound class: PSMA-targeting small molecule with NETA-based bifunctional chelator (radiotheranostic PSMA ligand)
Target / mechanism: PSMA (prostate-specific membrane antigen) targeting PMID 37375829
Clinical application: Imaging and treatment of prostate cancer PMID 37375829
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	93.6 ± 2.0%	>89%	3p-C-NETA-ePSMA-16	37375829 2023 Pharmaceuticals (Basel) Radiolabeling of 3p-C-NETA-ePSMA-16 with 177Lu in similar conditions gave low RCYs - high RCYs (93.6 ± 2.0; n = 3) were obtained when the reaction mixture was heated at 90 °C for 5 min

Need this precursor?We can point you to suppliers for [177Lu]Lu-3p-C-NETA-ePSMA-16, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 37375829. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37375829: '3p-C-NETA-ePSMA-16 (1 nmol) dissolved in H2O was added to the solution, followed by [111In]InCl3 (50 MBq, 370 MBq/mL) or [177Lu]LuCl3'. Stage set/updated at stage 39 from PMID 37375829: 'Therapy studies with short-lived radionuclides such as 213Bi could further elucidate the therapeutic potential of 3p-C-NETA-ePSMA-16 as a radiotheranostic.'.